What one share of Northwest Biotherapeutics holds
We are a biotechnology company focused on developing personalized immune therapies for cancer. We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer.
Northwest Biotherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.02 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.03 |
| Cash and investments | $0.00 |
| Debt | $0.01 |
| Book value | −$0.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | $0.07 | −$5.72 | $0.00 | −$1.94 | — | — |
| 2013 | $0.02 | −$2.00 | — | — | — | −$0.21 |
| 2014 | $0.02 | −$2.29 | — | — | — | −$0.51 |
| 2015 | $0.02 | −$1.48 | — | — | — | −$0.05 |
| 2016 | $0.01 | −$0.77 | — | — | — | −$0.17 |
| 2017 | $0.00 | −$0.31 | — | — | — | −$0.20 |
| 2018 | $0.00 | −$0.12 | — | — | — | −$0.09 |
| 2019 | $0.00 | −$0.04 | $0.00 | −$0.06 | — | −$0.07 |
| 2020 | $0.00 | −$0.73 | — | — | — | −$0.44 |
| 2021 | $0.00 | −$0.06 | — | — | — | −$0.13 |
| 2022 | $0.00 | −$0.10 | — | — | — | −$0.12 |
| 2023 | $0.00 | −$0.06 | — | — | — | −$0.06 |
| 2024 | $0.00 | −$0.07 | $0.00 | −$0.05 | — | −$0.07 |
| 2025 | $0.00 | −$0.04 | $0.00 | −$0.03 | — | −$0.04 |
Common questions about Northwest Biotherapeutics
How much does one share of Northwest Biotherapeutics earn?
Over the last 12 months, Northwest Biotherapeutics lost $0.02 for each share on $0.00 of sales.
Does Northwest Biotherapeutics pay a dividend?
Northwest Biotherapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Northwest Biotherapeutics’s book value per share?
Northwest Biotherapeutics’s book value is negative (−$0.03 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Northwest Biotherapeutics have?
Each share of Northwest Biotherapeutics has $0.00 of cash and investments and $0.01 of debt, as of June 30, 2026.
What is Northwest Biotherapeutics’s free cash flow per share?
−$0.03 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Northwest Biotherapeutics bought back shares?
Northwest Biotherapeutics’s share count rose about 12288% from 2012 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.